
    
      The study is a Phase I/II, open label, single-arm, multicenter study of LioCyx. Subjects with
      recurrent hepatitis B virus-related hepatocellular carcinoma who undergone liver
      transplantation will be enrolled.

      Approximately 6-12 subjects will be enrolled in Phase 1 dose regimen exploration, and
      approximately 60 subjects will be enrolled to characterize the safety and evaluate the
      efficacy of LioCyx"

      All subjects will be followed up for survival until death.
    
  